A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
ApexOnco Front Page
Recent articles
The first global phase 3 trial will be in first-line triple-negative breast cancer.
Pfizer moves to take PF-07934040 into its first clinical trial.
Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.
The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.
Supply continues to cause headaches for radiopharmaceutical developers.
As the dust settles on ASCO the weekend’s immediate winners and losers emerge.
A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.